Please assess the completion status of the following clinical trial:

Trial Title: Radiation Therapy, Cisplatin, and Etoposide in Treating Patients With Non-small Cell Lung Cancer That Cannot Be Removed by Surgery

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with confirmed unresectable Stage IIB or Stage III non-small cell lung cancer of any histologic-subtype appropriate for definitive concurrent chemotherapy and radiation as determined by multi-disciplinary assessment; all detectable tumor should be encompassable by radiation therapy fields, including both the primary tumor and the involved regional lymph nodes~* Granulocytes \>= 1500/ul~* Platelets \>= 100,000/ul~* Bilirubin \< 1.5 mg/dl~* Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase \[SGOT\]) \< 2 upper limit of normal (ULN)~* Creatinine clearance must be \> 60ml/min~* Eastern Cooperative Oncology Group (ECOG) 0 to 1~* Weight loss =\< 5% in the previous six months unless weight loss is intentional (per judgment of study medical doctor \[MD\])~* Forced expiratory volume in one second (FEV1) must be \>= 1.0 L~* Patients must sign a study-specific informed consent form prior to study entry~* Patients must have measurable disease on the 3D planning computed tomography (CT)~* Patient must have a completed 3D plan and the attending physician must have reviewed and approved the dose volume histograms as follows: total lung volume percentage receiving at least 20 Gy (V20) =\< 35%, and mean lung dose =\< 20 Gy~Exclusion Criteria:~* Mixed histology or undifferentiated small cell carcinoma, any stage~* Concurrent malignancy except non-melanomatous skin cancer or prior cancer if disease-free for one year or more~* Patients with malignant pleural effusions or significant pericardial effusions~* Pregnant or lactating females~* Severe neuropathy greater than or equal to grade 2~* Severe sensorineural hearing loss greater or equal to grade 2~* No clinically significant history of cardiac disease, (i.e. uncontrolled hypertension, unstable angina, congestive heart failure, myocardial infarction within the past year, or cardiac ventricular arrhythmias requiring medication)~* Any significant or severe medical conditions or psychiatric or social conditions that would preclude adherence to the protocol or compliance with study treatments

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment (radiation therapy and chemotherapy) (Type: EXPERIMENTAL): Patients undergo 3D-CRT or IMRT 5 days a week for 8 weeks. Patients also receive cisplatin IV over 60 minutes on days 1, 8, 28, and 36 and etoposide IV over 60 minutes on days 1-5, and 28-32.

Based on this trial design, predict the completion outcome and termination type (if applicable).